FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Instagram Outage Disrupts Thousands of U.S. Users 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SAN FRANCISCO, May 08, 2018 -- Nurix, Inc., a private drug discovery company, today announced the appointment of Dr. Nancy Pryer as the company’s chief development officer. Dr. Pryer will join Nurix’s executive management team to lead the company’s preclinical, translational and clinical drug development efforts.
“We are delighted to welcome Dr. Pryer to Nurix,” said Arthur T. Sands, M.D., Ph.D., chief executive officer of Nurix. “Her extraordinary depth of experience in oncology and drug development broadly will provide great value to Nurix as we advance our breakthrough science into human clinical studies.”
Dr. Pryer joins Nurix from BioMarin Pharmaceutical, where she served as vice president of translational sciences. In that role, she led the company’s efforts in biomarker discovery, bioanalytics, immunogenicity assessment and clinical pharmacology. Prior to joining BioMarin, Dr. Pryer held leadership roles in oncology drug discovery and translational development at Novartis Institutes for Biomedical Research, Raven, SUGEN and Onyx Pharmaceuticals. Dr. Pryer received her Ph.D. in biology from the University of North Carolina, Chapel Hill, and completed post-doctoral work in the lab of Dr. Randy Schekman at the University of California, Berkeley.
“This is an exciting time in the field of protein homeostasis and targeted protein degradation, as years of effort are yielding novel candidate therapeutics for oncology and other unmet medical needs,” said Dr. Pryer. “Throughout my career I’ve been passionate about evaluating drug mechanism of action to develop new therapies for select patient populations. I look forward to working with Arthur and the Nurix team to apply these translational medicine approaches as we move the Nurix pipeline through IND-enabling studies and into the clinic.”
About Nurix
Nurix, Inc. is a leader in the discovery of small molecules that modulate the ubiquitin proteasome system (UPS) to address significant, unmet medical needs. The UPS is a regulatory pathway that controls protein levels, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas. Nurix was founded by internationally-recognized experts in the ubiquitin proteasome field and is funded by leading life science investors Third Rock Ventures and The Column Group. In September 2015, Nurix and Celgene entered into a broad collaboration targeting protein homeostasis for next-generation therapies in oncology, inflammation and immunology. The company is headquartered in San Francisco, California. For more information, please visit http://www.nurix-inc.com.
Media Contact
Sara Zelkovic
LifeSci Public Relations
[email protected]
